About usPipelineSciencePartneringNews/EventsCareersContects

Projects

  • CT200
    The product is being developed for Behçet
  • CT327
    Is being developed as a novel topical treatment for psoriasis.
  • CT335
    A new systemic treatment for Behçet's Disease.
  • CT400
    The CT400 program is aimed at developing inhibitors of HGMB-1.
  • CT500
    The CT500 program is aimed at inflammatory disorders including Systemic Lupus Erythematosus.